PT-141 side effects from the phase 3 bremelanotide trials and FDA label: nausea, flushing, transient blood pressure changes, focal hyperpigmentation, and where the data runs out.
PT-141 (bremelanotide) has the most complete adverse-event record of any peptide in this catalogue — not because it is unusually risky, but because it went through two phase 3 trials and a full FDA review as VYLEESI, and the resulting label is public. That makes "PT-141 side effects" an unusually answerable question. The profile is dominated by nausea, flushing, and transient cardiovascular effects, and it carries one hard contraindication.
Almost every number below traces to one source: the phase 3 RECONNECT programme — two identical randomised, double-blind, placebo-controlled trials of subcutaneous bremelanotide 1.75 mg dosed on demand in premenopausal women with hypoactive sexual desire disorder, pooled safety population 627 treated and 620 placebo. FDA approval followed in 2019, and those incidence figures are the only large-sample, placebo-controlled adverse-event data the compound has.
That provenance matters. The population was female, premenopausal, and largely healthy; dosing was episodic rather than daily; the dose was fixed at 1.75 mg. Extrapolation beyond those conditions — to male subjects, higher doses, daily cadences — is inference, not evidence.
Reactions reported in the pooled phase 3 trials, bremelanotide versus placebo:
| Adverse reaction | Bremelanotide 1.75 mg (n=627) | Placebo (n=620) |
|---|---|---|
| Nausea | 40.0% | 1.3% |
| Flushing | 20.3% | 0.3% |
| Injection site reactions | 13.2% | 8.4% |
| Headache | 11.3% | 1.9% |
| Vomiting | 4.8% | 0.2% |
Nausea is the defining tolerability issue and the reason most discontinuations happened: it required anti-emetic therapy in 13% of treated subjects and led 8% to leave the trials. The label notes it improved for most subjects after the second dose — a tolerance pattern, not a resolved problem. Flushing at 20% against a 0.3% placebo background is the second signal, and mechanistically expected, since melanocortin agonism produces vasomotor effects. The placebo column deserves equal attention: injection site reactions ran 13.2% versus 8.4%, a real but modest increment, most of which is the needle rather than the peptide.
Bremelanotide transiently raises blood pressure and lowers heart rate after each dose. Clinical studies documented maximal increases of about 6 mmHg systolic and 3 mmHg diastolic, with heart rate reductions up to 5 beats per minute, generally resolving within 12 hours post-dose. Repeat dosing 24 hours apart did not produce additive effects.
A dedicated ambulatory blood pressure monitoring study in 397 subjects across 0.75, 1.25, and 1.75 mg doses found mean systolic and diastolic increases of roughly 3 mmHg confined to the four hours after administration, with peak elevations typically lasting under fifteen minutes, alongside heart rate reductions of about 4.6–6.6 bpm over the first eight hours. Roughly 7% of participants were withdrawn on prespecified blood pressure criteria, distributed about equally across treatment and placebo arms.
Small on average — but the label treats the mechanism as categorical rather than magnitude-dependent, listing uncontrolled hypertension and known cardiovascular disease as contraindications. The history behind that is instructive: an earlier intranasal formulation had development halted in the late 2000s over unacceptable blood-pressure elevations attributed to erratic bioavailability, and the compound was reformulated for subcutaneous delivery precisely to make exposure predictable.
Melanocortin agonism at MC1R drives melanogenesis, so pigmentation is an on-target effect rather than a contaminant. Frequency depends heavily on dosing density. At up to eight doses per month, 1% of phase 3 subjects reported focal hyperpigmentation, including the face, gingiva, and breasts. In a separate study using daily dosing for eight consecutive days, 38% developed focal hyperpigmentation, and subjects with darker skin were more likely to do so. Resolution after discontinuation was not confirmed in all cases.
That 1%-versus-38% gap is the single most useful safety fact about this compound: the pigmentation signal is a function of cumulative exposure, not of any individual dose. It is also the axis on which PT-141 differs most from its structural relative — see the Melanotan 2 side effects discussion for what sustained MC1R agonism looks like when pigmentation is the intended endpoint rather than an off-target one.
Two interaction signals appear on the label. Bremelanotide may significantly decrease systemic exposure of orally administered naltrexone, and concurrent use with oral naltrexone products indicated for addiction treatment is to be avoided. Separately, it slows gastric emptying, which can blunt or delay absorption of concomitant oral drugs — particularly those depending on rapid onset or a threshold concentration, with indomethacin given as the example.
The pharmacokinetics explain the short window on all of this: median Tmax is about one hour and terminal half-life is roughly 2.7 hours (range 1.9–4.0). Exposure is brief, which is why the labelled limits are cadence-based — no more than one dose in 24 hours, and more than eight doses per month is not recommended. The reconstitution and volume arithmetic behind any of those figures is covered in Peptide Dosing Math and How to Reconstitute Peptides, and the compound's mechanism and efficacy record in the PT-141 research overview.
The gaps are specific. There is no equivalently powered placebo-controlled adverse-event dataset in male subjects — the phase 2 male erectile-dysfunction work used the abandoned intranasal route, and current male use is off-label and clinic-reported rather than trial-derived. There is no long-horizon record; controlled exposure was episodic dosing over months, not years. Doses above 1.75 mg subcutaneous have no characterised tolerability profile. And hyperpigmentation reversibility is genuinely open, not merely under-reported. Read the label figures as what they are: a well-characterised short-term profile at one dose in one population, with an honest boundary around everything else.
What is the most common PT-141 side effect? Nausea, by a wide margin. It was reported by 40% of bremelanotide-treated subjects in the pooled phase 3 trials versus 1.3% on placebo, required anti-emetic therapy in 13%, and caused 8% to discontinue.
Does bremelanotide raise blood pressure? Yes, transiently. Studies documented maximal increases of about 6 mmHg systolic and 3 mmHg diastolic with a small reduction in heart rate, usually resolving within 12 hours. Uncontrolled hypertension and known cardiovascular disease are listed contraindications on the approved label.
Does PT-141 cause skin darkening like Melanotan 2? It can, and the rate depends on dosing frequency. At up to eight doses per month, 1% of phase 3 subjects reported focal hyperpigmentation; with daily dosing for eight days, 38% did. Darker skin phototypes were more affected, and resolution after stopping was not confirmed in all subjects.
Is the female trial data applicable to male subjects? Not directly. The controlled safety dataset comes from premenopausal women dosed on demand at 1.75 mg subcutaneously. There is no comparably powered placebo-controlled adverse-event dataset in men, so applying these incidence figures outside that population is inference rather than evidence.
